Premium
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C
Author(s) -
Freedman Neal D.,
Everhart James E.,
Lindsay Karen L.,
Ghany Marc G.,
Curto Teresa M.,
Shiffman Mitchell L.,
Lee William M.,
Lok Anna S.,
Di Bisceglie Adrian M.,
Bonkovsky Herbert L.,
Hoefs John C.,
Dienstag Jules L.,
Morishima Chihiro,
Abnet Christian C.,
Sinha Rashmi
Publication year - 2009
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.23162
Subject(s) - medicine , cirrhosis , gastroenterology , hepatitis c , liver biopsy , liver disease , steatosis , fibrosis , hepatology , fatty liver , population , alanine transaminase , confidence interval , biopsy , disease , environmental health
Higher coffee consumption has been associated inversely with the incidence of chronic liver disease in population studies. We examined the relationship of coffee consumption with liver disease progression in individuals with advanced hepatitis C–related liver disease. Baseline coffee and tea intake were assessed in 766 participants of the Hepatitis C Antiviral Long‐Term Treatment against Cirrhosis (HALT‐C) trial who had hepatitis C–related bridging fibrosis or cirrhosis on liver biopsy and failed to achieve a sustained virological response to peginterferon plus ribavirin treatment. Participants were followed for 3.8 years for clinical outcomes and, for those without cirrhosis, a 2‐point increase in Ishak fibrosis score on protocol biopsies. At baseline, higher coffee consumption was associated with less severe steatosis on biopsy, lower serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, alpha‐fetoprotein, insulin, and homeostatic model assessment (HOMA2) score, and higher albumin ( P < 0.05 for all). Two hundred thirty patients had outcomes. Outcome rates declined with increasing coffee intake: 11.1/100 person‐years for none, 12.1 for less than 1 cup/day, 8.2 for 1 to fewer than 3 cups/day, and 6.3 for 3 or more cups/day ( P ‐trend = 0.0011). Relative risks (95% confidence intervals) were 1.11 (0.76‐1.61) for less than 1 cup/day; 0.70 (0.48‐1.02) for 1 to fewer than 3 cups/day; and 0.47 (0.27‐0.85) for 3 or more cups/day ( P ‐trend = 0.0003) versus not drinking. Risk estimates did not vary by treatment assignment or cirrhosis status at baseline. Tea intake was not associated with outcomes. Conclusion: In a large prospective study of participants with advanced hepatitis C–related liver disease, regular coffee consumption was associated with lower rates of disease progression. (H EPATOLOGY 2009.)